Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin
This article was originally published in Pharmaceutical Approvals Monthly
Betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting
You may also be interested in...
The cresting wave of novel antithrombotic NDAs could mean 2010 will be a difficult year for FDA's Division of Cardiovascular and Renal Products, as the products have massive applications and tricky risk-benefit evaluations.
As Boehringer-Ingelheim scrambles to file its oral anticoagulant Pradaxa with FDA, likely for stroke prevention in patients with atrial fibrillation, physicians already have started weighing the pros and cons of the drug's two possible doses
The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use